DAZAMPLA
Live / Registered — Registered (as of 17 Oct 2023)
What this means for you
Registered since 17 Oct 2023. The owner can stop confusingly similar uses in the classes it covers; it stays on the register as long as the owner keeps up the maintenance filings (next due by 17 Oct 2029: the §8 declaration of use).
Record
- Serial number
- 97708461
- Registration number
- 7196195
- Mark type
- Word mark
- Filed
- 08 Dec 2022
- Published for opposition
- 01 Aug 2023
- Registered
- 17 Oct 2023
- Next maintenance filing
- §8 declaration of use, due by 17 Oct 2029 (grace period to 17 Apr 2030)
- Attorney of record
- Elizabeth K. Rucki
Goods and services
- Class 005 — Pharmaceuticals: Vaccines; Anti-infectives; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations for the treatment of infectious diseases, pain, inflammation, obesity and cognitive disorders; Pharmaceutical preparations for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, oncological, hepatological, respiratory, neurological, gastrointestinal, dermatological, psychiatric and immune system related diseases and disorders
Owner
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
- Glaxo Group Limited, Stevenage, GB
Prosecution history
- 17 Oct 2023 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 17 Oct 2023 — REGISTERED-PRINCIPAL REGISTER
- 01 Aug 2023 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 01 Aug 2023 — PUBLISHED FOR OPPOSITION
- 12 Jul 2023 — TEAS CHANGE OF CORRESPONDENCE RECEIVED
- 12 Jul 2023 — APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
- 12 Jul 2023 — TEAS CHANGE OF OWNER ADDRESS RECEIVED
- 12 Jul 2023 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 27 Jun 2023 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 26 Jun 2023 — ASSIGNED TO EXAMINER
- 05 Jan 2023 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
- 12 Dec 2022 — NEW APPLICATION ENTERED